Capital One Financial Weighs in on Immutep Limited’s FY2029 Earnings (NASDAQ:IMMP)

Immutep Limited (NASDAQ:IMMP) – Stock analysts at Capital One Financial boosted their FY2029 EPS estimates for Immutep in a research report issued on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotechnology company will post earnings per share of $0.28 for the year, up from their previous forecast of $0.27. Capital One Financial currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Immutep’s current full-year earnings is ($0.24) per share.

Separately, Robert W. Baird cut their target price on shares of Immutep from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, June 27th.

Immutep Trading Up 1.6 %

Immutep stock opened at $2.57 on Thursday. Immutep has a 12-month low of $1.58 and a 12-month high of $3.34. The firm has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $2.45.

Institutional Investors Weigh In On Immutep

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XY Capital Ltd acquired a new position in shares of Immutep during the 2nd quarter worth $105,000. Oracle Investment Management Inc. grew its stake in Immutep by 9.4% in the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after buying an additional 48,449 shares during the last quarter. Virtu Financial LLC grew its stake in Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 32,864 shares during the last quarter. XTX Topco Ltd acquired a new position in Immutep in the 2nd quarter valued at $26,000. Finally, Meridian Wealth Management LLC grew its stake in Immutep by 3.6% in the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 11,250 shares during the last quarter. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.